FASLODEX 500 mg: Dosing Regimen1
If you are a health care professional affiliated with an employer, institution, or committee, or practicing in a state that restricts what items you may receive from manufacturers, we ask that you not accept or download any restricted items from this site. If you are a health care provider practicing in Vermont, we are required by state law to deny you permission to download any items or review any journal articles made available on this site.
Dosing schedule: 500-mg dose given as 2 x 250-mg injections
FASLODEX 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5-mL injections, one in each buttock, on days 1, 15, 29 and once monthly thereafter.
FASLODEX is metabolized primarily in the liver. A 250-mg dose is recommended in patients with moderate hepatic impairment.* FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh Class C).
Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants.
How to administer FASLODEX
You will need Adobe Acrobat installed on your computer to view the dosing card. If you do not have it and would like to download, please click here.
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease
progression following antiestrogen therapy.
IMPORTANT SAFETY INFORMATION:
Click Here for Additional Safety Information
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to
any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.
OnCue - News for
Regularly updated articles cover a range of topics including treatment information, oncology conferences details, and patient resources.
Request to have an AstraZeneca representative contact you.
Request a Rep